22 results about "Dysphagia" patented technology

The application belongs to the technical field of dysphagia rehabilitation, and particularly relates to a cold stimulation device for dysphagia rehabilitation, which comprises a supporting column, a reciprocating electric telescopic rod coaxially and fixedly connected to one end of the supporting column, a semiconductor touch head fixedly connected to a telescopic end of the reciprocating electric telescopic rod, a biting seat fixedly connected to the supporting column, biting air bags fixedly and symmetrically connected to the biting seat, the biting air bags being communicated with the supporting column, and a detection tube fixedly connected to the biting seat. The oral cavity sealing mechanism automatically triggered by biting action can accurately detect the swallowing action according to the negative pressure of the oral cavity. After the effective swallowing action is detected, the stimulation can be paused through a delay start switch, the next round of training can be automatically started after the rest, and the timing and rhythm of each stimulation are ensured to be consistent with the physiological response. The normal exhalation can be realized while the oral cavity sealing space is formed, and the breathing safety is ensured.

This invention provides a method and system for risk warning of dysphagia based on multi-signal analysis. The method includes: acquiring surface electromyography (EMG) signals, bioimpedance signals, laryngeal vibration signals, and neck microenvironment temperature and humidity signals from the wearer's neck using a flexible wearable sensing unit; using the respiratory phase determined by the neck microenvironment temperature and humidity signals as a time reference, performing time alignment and preprocessing on the multimodal physiological signals to obtain multi-channel time-series data; extracting and fusing features from the multi-channel time-series data to generate a discriminative fusion feature vector; inputting the vector into a pre-trained classification model for real-time inference to identify swallowing function states, including effective swallowing, ineffective swallowing, and suspected aspiration; and generating a graded risk warning signal in response to the identified abnormal states. This invention solves the problems of motion artifact interference and time alignment through multimodal signal fusion and respiratory rhythm calibration, achieving accurate and continuous monitoring of dysphagia risk.

Edible foods which include a selection food and provided in a form that improves swallowing in the subject are provided. The compositions include an effective combination of foods that function as TRP agonists, to provide improve swallowing in a subject in need thereof. In some forms, the compositions include: (a) hydrocolloid such as gelatin and (b) liquid juice (preferably including electrolytes) / soup component, optionally in combination with one or more additional ingredients selected from (c) a spice, (d) sweetening agent, (e) an oil, (f) a flavoring acid, (g) cocoa and (h) a pepper.

The application belongs to the technical field of food processing, and particularly relates to egg white-chlorella compound protein gel and application thereof in preparation of dysphagia adaptive food. The application provides an egg white-chlorella compound protein gel, which is obtained by heating and cross-linking of egg white protein and chlorella protein dispersed in water. The gel has high protein density (protein content is greater than or equal to 12 w / w %) and low hardness (<120 g), and its swallowing adaptability meets the international dysphagia diet standardization initiative (IDDSI) 3-5 solid food standard, so that the eating needs of patients with moderate to severe dysphagia who cannot independently control liquid intake can be met, and a new food option with high nutritional density and excellent swallowing safety is provided for the patients, so that the nutritional status of the patients can be effectively improved and the life quality of the patients can be improved.

A probiotic microsphere with in-situ proliferation, its preparation method and application. The microsphere is prepared by a two-step Pickering double emulsion method, encapsulating probiotics and panax notoginseng saponins, and then mixed with sodium alginate and cross-linked by calcium ions. The structure significantly improves the survival rate of probiotics in simulated gastric juice, intestinal juice, heat treatment and antibiotic environment, and maintains high viable cell count during long-term storage. Co-encapsulated PNS and double emulsion stabilizer natural polysaccharide-protein nanocomposite can promote the proliferation of probiotics in-situ, increase their activity. In addition, the microsphere can effectively promote the colonization and proliferation of probiotics in the intestinal tract, enhance the oral bioavailability of bioactive ingredients, and is suitable for functional food, feed, biological medicine field, especially as 3D printing special medical food for dysphagia population and prevention and treatment of intestinal inflammatory diseases.

This invention discloses a device for screening dysphagia after stroke based on voice acoustic parameters, comprising a noise detection device, an input device, a processing device, and an output device. The noise detection device is used to collect measured values ​​of the patient's longest vocalization time (MPT), highest sound intensity (I_high), highest fundamental frequency (F0_high), lowest sound intensity (I_low), and fundamental frequency perturbation (Jitter). The input device is used to collect the patient's brainstem lesion assignment. The processing device is connected to both the noise detection device and the input device. The measured values ​​of the longest vocalization time, highest fundamental frequency, lowest sound intensity, and fundamental frequency perturbation are used as variables to calculate the measured value of the Voice Disorder Index (DSI). The measured values ​​of the brainstem lesion assignment, longest vocalization time, highest sound intensity, and DSI are used as variables to calculate the total score of the prediction model. The risk probability value of dysphagia in stroke patients is obtained based on the total score of the prediction model.

A system for a dysphagia patient 100 includes: an information acquisition unit 10 that acquires patient identification information 30 capable of identifying a patient and bed angle information 31 of the patient's bed 6 based on the patient's swallowing function; a storage unit 11 in which the patient identification information 30, location information 32 indicating one of an address of the bed 6, an address of a display device 3 installed in a location visible from the bed 6, and the patient's whereabouts, and the angle information 31 are stored in association with each other; and a control unit 12. The control unit 12 uses the patient identification information 30 to acquire the location information 32 and the angle information 31 associated with the patient identification information 30 from the storage unit 11, and uses the location information 32 to transmit the angle information 31 to at least one of the bed 6, the display device 3, and an information terminal 8 held by a caregiver for the patient's meal.

This disclosure relates to devices and methods for administering therapeutic compositions to the pharyngeal muscles. Specifically, the devices and methods of this disclosure may be used to treat or prevent dysphagia, including dysphagia associated with oculopharyngeal dystrophy (OPMD), in individuals suffering from or predisposed to dysphagia. In addition, this disclosure relates to devices and methods used to deliver modified adeno-associated virus (AAV) delivery vectors containing a "silence and substitution" DNA construct, including compositions containing a "silence and substitution" DNA construct.

A drainage device includes an elongate flexible conduit comprising a proximal end opening, a distal end opening and a lumen disposed therebetween. A multi-layer distal portion coaxially surrounding the lumen and having a porous outer surface layer, a porous interior layer and an intermediate absorbent layer therebetween. A drainage system and a device and method for treating dysphagia are also disclosed.

Provided are an oral dissolving film composition of rivaroxaban, a method for preparing same, and use thereof. The oral dissolving film composition comprises one or more of rivaroxaban and a pharmaceutically acceptable salt, hydrate, and solvate thereof as an active ingredient, and a film-forming material. Also, the present invention features a simple process, no sedimentation during the preparation of film solutions, qualified content uniformity, high drug loading capacity, and improved patient compliance, and is particularly suitable for patients with dysphagia.

This invention relates to the field of dysphagia assessment technology, specifically to a system and method for assessing postoperative dysphagia in patients with posterior fossa tumors. The method includes: acquiring electromyographic signals of swallowing-related muscle groups and ultrasound images of the esophagus; determining the behavioral fluency of the swallowing process based on changes in adjacent ultrasound frames; determining activation abnormality indicators by comparing the activation times of all muscle groups with standard activation states; performing delay analysis on electromyographic signals based on time-frequency transformation to determine the activation delay time; performing electromyographic signal correlation analysis on each muscle group with other muscle groups to determine the muscle group activation disorder coefficient; combining the activation delay time with electromyographic signal correlation analysis on each muscle group with other muscle groups to determine the muscle group activation disorder coefficient; and determining the likelihood of dysphagia based on behavioral fluency and the muscle group activation disorder coefficients of all muscle groups. This invention can effectively improve the accuracy and timeliness of dysphagia assessment.

The present application relates to a kind of swallowable composite gel based on soybean protein and rice starch and its preparation method and application.The method will be added in proportion to rice starch and soybean protein in deionized water mixing, and add different kinds and concentration of calcium salt, and prepare mixed system suspension.The suspension is preheated under constant temperature stirring at 60 DEG C, then quickly transferred to water bath and heated treatment.Cooling obtains soybean protein and rice starch composite gel containing different kinds and concentration of calcium salt.The present application makes full use of the physicochemical properties of protein and starch and its interaction, forms complex gel structure, thereby improving the texture and sensory characteristics of food.At the same time, by adding different calcium salt, the gel texture can be further adjusted and the nutritional value is strengthened, to meet the special needs of dysphagia population for food safety and suitable texture, to improve the effective scheme for the problem of dysphagia in elderly population, with good food application prospect.

This invention provides a cariprazine orally disintegrating film composition, its preparation method, and its application. The orally disintegrating film composition comprises an active ingredient, a film-forming material, and a plasticizer, wherein the active ingredient is selected from one or more mixtures of cariprazine, pharmaceutically acceptable salts of cariprazine, and their inclusion compounds. The orally disintegrating film composition of this invention has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without water, and rapid oral absorption. It also features a simple process, high drug loading capacity, and good drug content uniformity. The orally disintegrating film composition of this invention helps improve medication compliance, medication retention, and vomiting in patients with schizophrenia, and is particularly suitable for patients with swallowing difficulties, showing promising market prospects.

This invention relates to the field of dysphagia rehabilitation technology, specifically a dysphagia rehabilitation device. The device includes a housing with a squeezing chamber at its bottom and an operating chamber inside. A reciprocating slide rod is located inside the operating chamber, with one end extending into the squeezing chamber and fixedly connected to the middle of an elastic membrane. The bottom of the elastic membrane is fixedly connected to the inner side of the squeezing chamber. A guide slide rod is fixedly connected to the top of the reciprocating slide rod, and a guide sleeve is slidably fitted onto the top of the guide slide rod. Patients can independently adjust their mouth volume by hooking a movable handle. The hooking amplitude is linearly negatively correlated with the mouth volume, adapting to the different needs of patients with mild to moderate dysphagia. Combined with signal feedback from the sliding resistor and the brush slide rod, the device adjusts the food temperature in real time based on the current mouth volume value, improving adjustment accuracy and effectively enhancing the patient's autonomy and dignity in eating, while reducing the workload for caregivers.

An oral liquid composition according to the present invention comprises tegoprazan or a pharmaceutically acceptable salt thereof as an active ingredient, a solubilizing agent, and an extra solvent. The present invention has improved the problem of residual foreign body sensation of orally disintegrating tablets conventionally developed for patients with dysphagia. In addition, it is possible to provide a new treatment option for an increasing patient group with gastric acid-related diseases by securing excellent stability of the active ingredient in a solution state, which is a characteristic of an oral liquid dosage form, and presenting a dosage form that ensures uniformity of a preparation.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

This invention relates to the field of rehabilitation medical equipment technology, and more particularly to a percutaneous auricular vagus nerve stimulation system and method for treating dysphagia after stroke. The system includes: a positioning module, which collects skin impedance distribution information in the concha region and determines the target physical coordinates based on the skin impedance distribution information; a titration module, which, based on the target physical coordinates, obtains the sensory threshold and pain threshold of the subject to electrical stimulation and calculates and generates an individualized intensity benchmark; and a signal module, which, after establishing the individualized intensity benchmark, simultaneously collects the submental muscle group signal and respiratory waveform of the subject and maps them to form a multimodal feature vector. In this invention, the output of the biomimetic frequency-modulated pulse is dynamically synchronized with the patient's spontaneous exhalation phase, effectively improving the physiological coordination of breathing and swallowing during the intervention process and reducing the risk of adverse reactions such as airway aspiration or coughing during electrical stimulation therapy.

The present application relates to the technical field of medical devices, and discloses a cold stimulation device for rehabilitation treatment of dysphagia, which comprises a device main body, an adjusting assembly, a supporting assembly, a stimulating assembly, a guiding assembly, a chin supporting piece, a head supporting piece, a touch screen PLC controller and two fixing assemblies; the adjusting assembly is vertically fixed on the front side of the device main body and used to drive the supporting assembly to move up and down; the stimulating assembly is detachably installed on the supporting assembly and comprises a cold water storage bottle and a disposable stimulating head; the chin supporting piece is slidably installed on the guiding assembly; the head supporting piece is rotatably installed on the front side of the device main body; and the two fixing assemblies are symmetrically arranged on the two sides of the device main body and used to fix the device on a table top; the present application is simple and convenient to operate, safe and sanitary, has stable and persistent stimulation effect, is highly adaptable, has high comfort level, and is convenient to install, and thus solves the problems of complicated operation and cross infection in the prior art.

The application discloses cilostazol dextrophan sublingual tablets and a preparation method thereof. The application effectively solves the technical bottleneck that cilostazol cannot be quickly dissolved due to poor solubility by optimizing the types and proportions of excipients; and by creatively adding sodium bicarbonate and citric acid, the dual technical targets of 'fast dissolution + high hardness' are unexpectedly achieved, the bioavailability of cilostazol is significantly improved, and the drug effect of cilostazol can be quickly exerted within the golden treatment period of acute cerebral stroke. Meanwhile, the drug composition process is good in feasibility, the prepared sublingual tablets are excellent in disintegration performance, can adapt to the drug administration needs of patients with dysphagia, completely meet the clinical application and pharmaceutical quality standards, and have significant clinical value and industrialization potential.

The present invention relates to an oral pharmaceutical composition comprising a therapeutic agent for gastroesophageal reflux disease, which uses a water-insoluble polymer to mask bitterness and improve dosing convenience. The composition according to the present invention can improve dosing convenience for elderly patients suffering from gastrointestinal diseases and patients complaining of dysphagia symptoms.